Dr. Kalfus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
251 Central Park W
New York, NY 10024Phone+1 917-817-7517
Education & Training
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1986 - 1990
Albert Einstein College of MedicineClass of 1986
Certifications & Licensure
NY State Medical License 1989 - 2025
Clinical Trials
- Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease Start of enrollment: 2017 Mar 18
Publications & Presentations
PubMed
- Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn's Disease.David Y Graham, Saleh A Naser, Thomas Borody, Zbigniew Hebzda, Harry Sarles
Antibiotics. 2024-07-25 - 28 citationsComparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies.Kristina G. Hulten, Robert M. Genta, Ira N. Kalfus, Yi Zhou, Hongjun Zhang
Gastroenterology. 2021-07-19 - 11 citationsRifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial.Ira N. Kalfus, David Y. Graham, Dennis S Riff, Raymond M Panas
Antibiotics. 2020-10-09
Press Mentions
Attune Pharmaceuticals Bags $23M for Oral HAE DrugJanuary 23rd, 2019
Attune Pharmaceuticals Announces Positive Phase 1 Results for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAEJanuary 22nd, 2019
H. Pylori Drug Achieves Positive Results in Phase 3 StudyDecember 13th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
